Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Quiz|Articles|July 24, 2026
OncLive Weekly News Quiz (7/24/2026): Did You Miss Crucial Pancreatic, Lung, and Prostate Cancer Updates?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
The FDA accepted the NDA for daraxonrasib (RMC-6236) in previously treated metastatic pancreatic ductal adenocarcinoma, based on the phase 3 RASolute 302 trial (NCT06625320). What type of agent is daraxonrasib?
Advertisement
Related to this article
In case you missed any, check out our recap of the episodes of OncLive On Air that aired in June 2026.
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
The FDA approved a bioequivalent formulation of olaparib for use in previously approved cancer indications.
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Teclistamab plus talquetamab met the primary PFS end point and improved overall survival in relapsed/refractory multiple myeloma in MonumenTAL-6.
Advertisement
Advertisement
Trending on OncLive
1
Dr Pant on the Potential Significance of Daraxonrasib for PDAC Management
2
Breast Cancer Buzz at ASCO 2026: De-Escalation Strategies, Targeted Therapies, and More
3
Dr Lee on the Optimal Duration of Adjuvant Osimertinib in EGFR+ NSCLC
4
Dr Cummings on the Utility of Adjuvant Immunotherapy Alone in Early-Stage NSCLC
5